News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
571,914 Results
Type
Article (41000)
Company Profile (226)
Press Release (530688)
Section
Business (163682)
Career Advice (2050)
Deals (29839)
Drug Delivery (103)
Drug Development (76397)
Employer Resources (152)
FDA (14743)
Job Trends (12904)
News (290707)
Policy (28499)
Tag
Academia (2286)
Alliances (42410)
Alzheimer's disease (1113)
Approvals (14672)
Artificial intelligence (136)
Bankruptcy (271)
Best Places to Work (9994)
Biotechnology (120)
Breast cancer (111)
Cancer (1062)
Cardiovascular disease (97)
Career advice (1706)
Cell therapy (221)
Clinical research (61313)
Collaboration (362)
Compensation (124)
COVID-19 (2393)
C-suite (90)
Data (1062)
Diabetes (140)
Diagnostics (5168)
Drug pricing (97)
Earnings (61558)
Employer resources (138)
Events (82221)
Executive appointments (281)
FDA (15241)
Funding (320)
Gene therapy (178)
GLP-1 (608)
Government (4040)
Healthcare (15716)
Infectious disease (2479)
Inflammatory bowel disease (108)
Interviews (343)
IPO (13384)
Job creations (3256)
Job search strategy (1475)
Layoffs (376)
Legal (6122)
Lung cancer (183)
Manufacturing (175)
Medical device (10125)
Medtech (10130)
Mergers & acquisitions (16528)
Metabolic disorders (421)
Neuroscience (1393)
NextGen Class of 2024 (5676)
Non-profit (3780)
Northern California (1241)
Obesity (253)
Opinion (227)
Patents (96)
People (47445)
Pharmaceutical (93)
Phase I (18527)
Phase II (27033)
Phase III (20699)
Pipeline (432)
Postmarket research (2332)
Preclinical (7432)
Radiopharmaceuticals (259)
Rare diseases (227)
Real estate (5001)
Regulatory (19588)
Research institute (2138)
Resumes & cover letters (319)
Southern California (1102)
Startups (3517)
United States (11301)
Vaccines (537)
Weight loss (206)
Date
Today (119)
Last 7 days (688)
Last 30 days (3321)
Last 365 days (31481)
2024 (28832)
2023 (34889)
2022 (45028)
2021 (48521)
2020 (46970)
2019 (40123)
2018 (30670)
2017 (29284)
2016 (28240)
2015 (32618)
2014 (25253)
2013 (20952)
2012 (22320)
2011 (23048)
2010 (20822)
Location
Africa (752)
Arizona (102)
Asia (37017)
Australia (5848)
California (2793)
Canada (1130)
China (232)
Colorado (127)
Connecticut (141)
Europe (80422)
Florida (431)
Illinois (306)
Indiana (162)
Kansas (88)
Maryland (496)
Massachusetts (2209)
Michigan (115)
Minnesota (182)
New Jersey (866)
New York (827)
North Carolina (631)
Northern California (1241)
Ohio (128)
Pennsylvania (662)
South America (1037)
Southern California (1102)
Texas (361)
Washington State (276)
571,914 Results for "ra pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).
June 17, 2024
·
7 min read
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Press Releases
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
October 25, 2024
·
10 min read
Press Releases
Aqtual Presents New Data on Development of RA Therapy Selection Test at ACR Convergence 2024
November 18, 2024
·
3 min read
Press Releases
SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024
November 18, 2024
·
5 min read
Drug Development
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.
April 8, 2024
·
8 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
1 of 57,192
Next
